Roche’s Lunsumio Meets Primary Endpoint in Phase III Follicular Lymphoma Trial

The read-through here is regulatory and competitive rather than scientific: hitting a primary endpoint in a Phase III FL study is the kind of milestone that supports filing and label expansion, and Roche has not yet disclosed the magnitude of the benefit. That gap matters, because the commercial question is whether Lunsumio's profile can hold up against entrenched FL options, not simply whether it beat its comparator. Whether the company releases the underlying data, and how regulators treat the endpoint, is the open question.